Study title: Minizideď (Brand of Prazosin/Polythiazide) Tablets (0.5 mg/0.25 mg) Clinical Experience in a Non-Comparative, Multicenter Trial
Type of medicine: Medicines containing chemical active substances | |||||
Therapeutic area: Cardiovascular Diseases | |||||
Brands: Please see report | |||||
MAH holders: Please see report | |||||
Assessment: | |||||
Active substance: PRAZOCIN /POLYTHIAZIDE | |||||
ATC code: C02CA01 | |||||
Document link: MZ-76-01 and MZ-76-02 EMA Pediatric Web Synopsis.pdf | |||||
Document date: 2013-06-07 | |||||
Study number: MZ-76-02* | |||||
EudraCT number: | |||||
Scope of study: Clinical | |||||
Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
- | - | - | - | - |